2022年9月30日

海豚屬醫療技術公司宣布關閉3000萬D係列融資以推動全球商業化的SoftVue 3 D整個乳房超聲波斷層掃描係統(SoftVue)。圓吸引了新的和現有投資者的參與,包括植物園,Beringea,北海岸技術投資者、風險投資家、Hopen生命科學投資,奧克菲企業。的基金關閉之前宣布第一個SoftVue係統出售,並將相關癌症研究所,底特律,技術最初的地方。“每天變得越來越明顯,我們有了一個改變遊戲規則的技術將致密的乳房檢查,”Mark j . Forchette說海豚屬醫療技術的總裁兼首席執行官。“當潛在客戶聽說SoftVue發現更多的癌症,提供了一種特殊病人的經驗和有效的病人工作流的同一天,乳房x光檢查沒有昂貴的員工增加,他們認識到他們的病人的價值。係列D將支持所需要的強大的商業策略和努力幫助網站快速對病人采用此解決方案。“百分之四十的婦女在美國有致密的乳房組織,和他們有一個four-to-six-time更大的患乳腺癌的風險。乳房x光檢查獨自想念大約一半的癌症婦女致密乳房,密集的組織和癌症都出現在乳房x光片中白色。SoftVue解決未滿足臨床需要,提供了一種新的年度篩選解決方案這個曆史上的人口。SoftVue表示作為兼職數字乳房x光檢查篩選的無症狀婦女致密的乳房組織。SoftVue提高致密的乳房篩查和識別20%更多的癌症與更大的準確性和活檢可能少於完整場數字乳房x光檢查(FFDM)。 The SoftVue exam is completed with no compression or radiation, and its PMA indication for use allows SoftVue exams to be performed at the same appointment as screening mammograms, facilitating a streamlined workflow and rapid delivery of results. “Our board of directors and investors are very excited to launch into commercial activities with SoftVue,” said Paul McCreadie, Delphinus Medical Technology’s board chairman and Partner and Chief Operating Officer at Arboretum Ventures. “The successful completion of a rigorous clinical study that resulted in the PMA approval we received last year for dense breast screening will allow the Delphinus team to leverage the unique technology of SoftVue to change the paradigm for dense breast screening and help millions of women receive superior care. We invest to allow breakthrough innovations to serve patients, and Delphinus is perfectly poised to do exactly that.” [Source(s): Delphinus Medical Technologies Inc, Business Wire] Share: